Scalper1 News
In recent decades, high cholesterol has been Big Pharma’s gravy train. The statins, oral drugs that lower “bad” cholesterol, turned into the best-selling drugs in history, with Pfizer’s Lipitor peaking at nearly $14 billion in 2006 sales. Now, however, all the statins have gone off-patent or are about to. So Pfizer (PFE) and a passel of other companies — led by Amgen (AMGN), Regeneron (REGN) and Regeneron’s partner Sanofi (SNY) — are turning to a Scalper1 News
Scalper1 News